Considering investment into a biotech, diagnostics, or medical device company?

Financial investment is not unlike facing down a heart disease or cancer: it pays well to assess all options in a sophisticated, independent, and timely manner. On the first try. You benefit short-term and long-term.

Sure, you’ve already done due diligence in-house and talked to several industry insiders.

But consider this: as in a serious medical, many experts you approach have a vested interest to please you. Prestige of your firm will rub off them. Future work as a go-to expert or Advisory Board member entices them. Bragging rights of “working with famous XYZ Capital” excite them. This could skew their views on your prospective investment’s technology. Yet you carry al risk – and they don’t.

In-house teams often pick due diligence experts from a limited circuit of advisers that cater to VC/PE firms – the “usual suspects”. It is similar to any hospital or physicians’ group practice – referrals usually follow a predetermined and limited pattern developed over decades and cemented by existing business and personal relationships. This can limit your view of the technology you are about to invest in, just as it often limits patients’ options to find best solutions for a medical problem.

We don’t have a set list of medical experts. We are not limited by any university, company, or country. We always find and approach experts based purely on how well they fit task at hand. Whether you are a top-brand VC, a small family fund, or a private person – we get world’s best-fitting experts to review any biomedical technology for you, and we insulate you from any bias by technical experts we approach.

Take a look at the caliber of medical experts we work with:

1. 1. We start with reviewing information about a company and/or technology that you share with us. We then conduct a focused discovery interview with a relevant member of your team about potential investment target:

      1.1. Your current thinking about this target
      1.2. Key issues that can make or break your decision regarding this target.
      1.3. List of questions you are concerned with already about a given technology.

1. 1. We review a market niche of your investment target: technology, competitors, trends. Then we proceed with identification of technical experts.

      2.1. We find and select world’s top scientific and medical experts whose lifetime work and expertise precisely fits key areas of planned due diligence.
      2.2. We use medical literature search, international conference materials, and recommendations from our extensive global network of medical experts.
      2.3. We anonymously pre-screen a short-list of experts found during the search for their fit and feedback on the potential in-depth discussion of the due diligence subject. Names of investors are never shared with experts. It’s your explicit choice whether to let us share potential investment target’s name.

1. 1. We conduct anonymous interviews with a panel of selected experts (number of experts depends on a category of service).

      3.1. Each expert is interviewed anonymously and independently of any other experts on a panel.
      3.2. Experts never know the names of investors or target companies (unless requested otherwise by investors). This ensures independence and objectivity of their opinion.
      3.3. We ask experts all questions that you convey to us during our discovery interview and all questions that we think should be asked about this technology and potential market adoption.

   2. We formulate a written focused due diligence report for you.

      4.1. Report incorporates and dissects all communication and views from our expert panel.
      4.2. Report includes our view of technology and market potential.
      4.3. Report includes references to relevant scientific articles and other materials.

1. We follow up with you after you’ve had a chance to review our due diligence report. If there are specific follow-up questions, we can revert to experts for clarification and elaboration of their views.